Godínez-Palma S, González-González E, Ramírez-Villedas F, Garzón-Guzmán C, Vallejo-Castillo L, Carballo-Uicab G, Marcelín-Jiménez Gabriel, Batista D, Pérez-Tapia SM, Almagro JC. Efficacy, pharmacokinetic and toxicity profiles of a broadly SARS-CoV2 neutralizing antibody. Viruses. 15: 1733. 2023.

Guzmán-Bringas OU, Gómez-Castellano K, González-González E, Salinas-Trujano J, Vázquez-Leyva S, Vallejo-Castillo L, Pérez-Tapia SM, Almagro JC. Discovery and optimization of neutralizing SARS-CoV-2 antibodies using ALTHEA Gold Plus Libraries™. Int. J. Mol. Sci. 24: 4609. 2023.

Almagro JC, Mellado-Sánchez G, Pedraza-Escalona M, Pérez-Tapia SM. Evolution of approved anti-SARS-COV-2 therapeutic antibodies. Int. J. Mol. Sci. 23: 9763. 2022.

Pedraza-Escalona M, Guzmán-Bringas O, Arrieta-Oliva I, Gómez-Castellano K, Salinas-Trujano J, Torres-Flores J, Muñoz-Herrera JC, Camacho-Sandoval R, Contreras-Pineda P, Chacón-Salinas R, Pérez-Tapia SM, Almagro JC. Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. BMC Infectious Diseases. 21: 1121, 2021.

Almagro JC, Pedraza M, Arrieta HI, Pérez-Tapia SM. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies. 8: 44, 2019.

Almagro JC, Mascioni A. Developability Assessment of Biologic Drugs. 195-220. In: Developability of Biologics: Safe and Cheaper Medicines via Computation. Ed. Sandeep K. CRC press. 2015.

Almagro JC, Kodangattil S. Novel generation of antibody based therapeutics. 147-170. In: Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Eds Singh M and Salnikova M. Elsevier. 2015.

Almagro JC, Kodangattil S, Li J. Humanized Antibodies. In: Making and Using Antibodies. 395-419. Eds. Howard GC and Matthew R and Kaser MR. 2nd edition. CRC Press. 2013.

Brezski R, Almagro JC. Application of Antibody Engineering in Development of Next Generation Antibody-Based Therapeutics. In: Development of Antibody-Based Therapeutics. 65-93. Eds. Tabrizi MA, Bornstein GG, Klakamp SL. Springer. 2012.

Almagro JC, Strohl WS. Antibody Engineering: Humanization, Affinity Maturation and Selection Methods. 309-334. In: Therapeutic Monoclonal Antibodies: From Bench to Clinic. Ed. Zhiqiang An. John Wiley & Sons, Inc. 2009

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Neutralizing human anti-CD27 antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 05/19/2020. US Patent: 11,732,050. Issued: 08/22/2023.

Manning PT, Puro R, Almagro JC. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,692,035. Issued: 07/04/2023.

Puro R, Hiebsch RR, Capoccia BJ., Andrejeva G, Almagro JC, Pereira DS. Therapeutic SIRP-alpha. antibodies. Assignee: Arch Oncology, Inc. US Patent: 11,202,828. Issued: 12/21/2021.

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating osteoarthritis with human oncostatin M antibodies. Assignee: Janssen Biotech, Inc. Priority Date: 12/10/2018. US Patent: 10,941,197. Issued: 03/09/2021.

Manning PT, Puro R, Almagro JC, Karr RW. Therapeutic CD47 antibodies. Assignee: Arch Oncology, Inc. Priority Date: 02/08/2019. US Patent: 10,844,124. Issued: 11/24/2020.

Gulla SV, Huard C, Buhlmann, JE, Almagro JC, Kodangattil SR, Coyle AJ. Interferon Beta Antibodies and Uses Thereof. Assignee: PFIZER, INC. Priority Date: 04/29/2016. US Patent: 10,829,553. Issued: 11/10/2020.

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,689,453. Issued: 06/23/2020.

Chen J, Fransson J, Fursov N, Hamel D, Malia T, Obmolova G, Ort T, Rycyzyn M, Scully M, Sweet R, Teplyakov A, Wheeler J, Almagro JC. Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies. JANSSEN BIOTECH, INC. US Patent: 10,301,392. Issued: 05/28/2019.

Manning P, Puro R, Almagro JC, Karr RW. Therapeutic CD47 Antibodies. US Patent: 10,239,945. Assignee: Arch Oncology, Inc. Issued: 03/26/2019.

Almagro JC, DuBell W, Fransson J, Pardinas J, Raghunathan G. Method of treating idiopathic pulmonary fibrosis by administering human oncostatin M antibodies. JANSSEN BIOTECH, INC. US Patent: 10,179,812. Issued: 01/15/2019.

Almagro JC, Pedraza M, Arrieta HI, Pérez-Tapia SM. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies. 8: 44, 2019.

Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Frontiers in Immunology 8: 1751, 2017.

Finlay WJJ, Almagro JC. Natural and Man-made V-region repertoires for Antibody Discovery. Frontiers in Immunology. 3: 1-18, 2012.

Gilliland GL, Luo J, Vafa O and Almagro JC. Leveraging SBDD in protein therapeutic development: antibody engineering. Methods in Molecular Biology. 841: 321-349, 2012.

Almagro JC, Fransson J. Humanization of antibodies. Frontier in Biosciences. 13:1619-1633, 2008.